Dermata Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Dermata Therapeutics Stock-Based Compensation Growth & History (DRMA)
Dermata Therapeutics's stock-based compensation was $143,732 for fiscal 2025.
View full Dermata Therapeutics company overviewDermata Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $143,732 | −$513,917 | −78.14% |
| 2024 | 2024-12-31 | $657,649 | $135,567 | +25.97% |
| 2023 | 2023-12-31 | $522,082 | −$408,243 | −43.88% |
| 2022 | 2022-12-31 | $930,325 | −$975,083 | −51.17% |
| 2021 | 2021-12-31 | $1.9M | $1.9M | — |
| 2020 | 2020-12-31 | $0 | — | — |
Dermata Therapeutics quarterly stock-based compensation
Q1.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $41,780 | $2,546 | +6.49% |
| Q1 2026 | 2026-03-31 | $43,278 | $6,089 | +16.37% |
| Q4 2025 | 2025-12-31 | $29,469 | −$346 | −1.16% |
| Q3 2025 | 2025-09-30 | $37,840 | $16,848 | +80.26% |
| Q2 2025 | 2025-06-30 | $39,234 | $19,626 | +100.09% |
| Q1 2025 | 2025-03-31 | $37,189 | −$550,045 | −93.67% |
| Q4 2024 | 2024-12-31 | $29,815 | −$98,653 | −76.79% |
| Q3 2024 | 2024-09-30 | $20,992 | −$110,185 | −84.00% |
| Q2 2024 | 2024-06-30 | $19,608 | −$111,569 | −85.05% |
| Q1 2024 | 2024-03-31 | $587,234 | $455,974 | +347.38% |
| Q4 2023 | 2023-12-31 | $128,468 | −$92,422 | −41.84% |
| Q3 2023 | 2023-09-30 | $131,177 | −$103,806 | −44.18% |
| Q2 2023 | 2023-06-30 | $131,177 | −$130,395 | −49.85% |
| Q1 2023 | 2023-03-31 | $131,260 | −$81,620 | −38.34% |
| Q4 2022 | 2022-12-31 | $220,890 | −$267,827 | −54.80% |
| Q3 2022 | 2022-09-30 | $234,983 | $92,328 | +64.72% |
| Q2 2022 | 2022-06-30 | $261,572 | $147,585 | +129.48% |
| Q1 2022 | 2022-03-31 | $212,880 | −$947,169 | −81.65% |
| Q4 2021 | 2021-12-31 | $488,717 | — | — |
| Q3 2021 | 2021-09-30 | $142,655 | $142,655 | — |
| Q2 2021 | 2021-06-30 | $113,987 | — | — |
| Q1 2021 | 2021-03-31 | $1.2M | −$179,944 | −13.43% |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $1.3M | — | — |
Dermata Therapeutics stock-based compensation trends
Over the last five fiscal years, Dermata Therapeutics's stock-based compensation increased from $0 to $143,732, a change of $143,732. The latest reported quarter, Q2 2026, shows $41,780.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dermata Therapeutics source filings ↗